English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Procalcitonin (PCT) is a biomarker which may have greater specificity than other pro-inflammatory markers in identifying bacterial infection and may aid in antimicrobial stewardship in COVID-19 patients. Methods A PCT assay by Abbott diagnostics was introduced in our hospital in November 2020. Over a 12 week period, we prospectively recorded all PCT results on in-patients with COVID-19 admitted to the ICU, as well as stewardship actions taken following discussion with the ICU physicians. Microbiology records were reviewed to ascertain whether bacterial infection was subsequently confirmed. Results Sixty-four PCT results were recorded on 27 patients (Table 1). Antimicrobials were discontinued on 12 occasions and withheld on 16 occasions where PCT was &amp;lt;0.5 ng/mL. No cases of confirmed bacterial infection were diagnosed in patients with PCT concentrations of &amp;lt;0.05 ng/mL; however definite bacterial infection was confirmed in two patients (one case of Staphylococcus aureus bloodstream infection; one case of Staphylococcus epidermidis CVC infection), and bacterial infection was designated probable in five patients with PCT ≥0.05 ng/mL and &amp;lt;0.5 ng/mL. Conclusions PCT may be a useful tool in enabling antimicrobial stewardship actions in patients with severe COVID-19, but results need to be interpreted within the clinical context.

P36 Procalcitonin as an antimicrobial stewardship tool in the COVID-19 era: a single centre experience